Source:http://linkedlifedata.com/resource/pubmed/id/14534693
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2003-10-9
|
pubmed:abstractText |
To test the hypothesis that genetically modified bone marrow-derived endothelial progenitor cells (EPCs) can be effective carriers of therapeutic agents to tumor sites, we utilized our conditionally immortalized endothelial progenitor cell line, TR-BME-2. In the syngenic rat, systemically injected TR-BME-2 cells were immediately distributed to the organs (lung, bone marrow, peripheral blood, liver, spleen). Trapped cells were cleared within 4 days, but selective accumulation in the Walker256 tumor was maintained for over 4 days. The tumor growth was enhanced by administration of TR-BME-2 cells. It is suggested that accumulated TR-BME-2 differentiated to tumor vasculature, increased the tumor blood supply, and thereby increased the tumor volume. We conducted IL-12 gene transfection of TR-BME-2 cells with a virus vector in vitro, and used the resultant IL-12-secreting TR-BME-2 to deliver IL-12, which strongly activates cytotoxic lymphocytes and natural killer cells, to the tumor site in vivo. However, the tumor-progressive character of TR-BME-2 offset the anti-tumor effect of IL-12. Nevertheless, our results suggest that gene-transfected EPCs could be useful as a tumor-specific drug delivery system, especially if the tumor vasculature-promoting effect of EPCs can be blocked.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
1021-335X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1765-9
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:14534693-Animals,
pubmed-meshheading:14534693-Animals, Genetically Modified,
pubmed-meshheading:14534693-Cell Line, Tumor,
pubmed-meshheading:14534693-Disease Progression,
pubmed-meshheading:14534693-Endothelium, Vascular,
pubmed-meshheading:14534693-Fluorescent Dyes,
pubmed-meshheading:14534693-Gene Therapy,
pubmed-meshheading:14534693-Interleukin-12,
pubmed-meshheading:14534693-Microscopy, Fluorescence,
pubmed-meshheading:14534693-Neoplasm Transplantation,
pubmed-meshheading:14534693-Neoplasms,
pubmed-meshheading:14534693-Organic Chemicals,
pubmed-meshheading:14534693-Rats,
pubmed-meshheading:14534693-Stem Cells,
pubmed-meshheading:14534693-Time Factors,
pubmed-meshheading:14534693-Tissue Distribution,
pubmed-meshheading:14534693-Transfection
|
pubmed:articleTitle |
Study of cancer gene therapy using IL-12-secreting endothelial progenitor cells in a rat solid tumor model.
|
pubmed:affiliation |
Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113-8677, Japan.
|
pubmed:publicationType |
Journal Article
|